Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer

NCT06783140 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer, Advanced or Metastatic
BRCA1/2 Mutation
PALB2 Gene Mutation

Interventions

DRUG: Nab paclitaxel
DRUG: Gemcitabine
DRUG: Cisplatin

Sponsor

University Health Network, Toronto